Amphastar Pharmaceuticals (AMPH) PT Lowered to $20 at Jefferies
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- SpaceX shares fall as second lockup period ends
- Supermicro probe finds no senior management link to export violations
- Hertz Global amends voting agreement with CK Amarillo after lawsuit
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2017
May 8, 2017 4:05 PM EDTRANCHO CUCAMONGA, Calif., May 08, 2017 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) (Amphastar or the Company) today reported results for the three months ended March 31, 2017.
First Quarter Highlights
Net revenues of $56.7 million for the first quarterGAAP net income of $0.9 million, or $0.02 per diluted share, for the first quarterAdjusted non-GAAP net income of $4.5 million, or $0.09 per diluted share, for the first quarterDr. Jack Zhang, Amphastars CEO, commented:Â We continue to execute on our... More
